Program
Triamcinolone Acetonide
Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.
Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.
Drug pageTriamcinolone Acetonide: every studyMany companies study it; this page follows only the 20 they lead. All 194 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Clearside Biomedical | 70 open or running | phase 3since Oct 28, 2015 | Feb 5, 2013 | none ahead |
| Pacira BioSciencesits history only | 21 open or running | phase 3since Feb 13, 2024 | Feb 13, 2024 | Dec 2026phase 3 · NCT06269705 |
| Sanofiits history only | 20 open or running | phase 3since Jun 26, 2006 | Jun 26, 2006 | none ahead |
| Alconits history only | 10 open or running | phase 3since Sep 19, 2007 | Sep 19, 2007 | none ahead |
| Biosplice Therapeuticsits history only | 10 open or running | phase 1since Oct 6, 2020 | Oct 6, 2020 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Harrowits history only | 11 open or running | phase 3since Sep 14, 2026 | Sep 14, 2026 | Dec 2026phase 3 · NCT07832552 |
| Merckits history only | 10 open or running | phase 2since Jun 4, 2008 | Jun 4, 2008 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Oct 19, 2005 | Oct 19, 2005 | none ahead |
| Oxularits history only | 10 open or running | phase 2since Aug 20, 2022 | Aug 20, 2022 | none ahead |
| PT. Prodia Stem Cell Indonesiaits history only | 10 open or running | phase 2since Mar 26, 2020 | Mar 26, 2020 | none ahead |
| SurModicsits history only | 10 open or running | phase 1since Jun 4, 2009 | Jun 4, 2009 | none ahead |
Also a collaborator on its studies: QLT.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Clearside Biomedical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2013First study: phase 2 study in UveitisFirst studyNCT01789320 · 11 enrolled · United States
- Oct 28, 2015Phase 3 study in UveitisNCT02595398 · 160 enrolled · United States, India, Israel
- Oct 25, 2016Phase 2 study in Diabetes MellitusNCT02949024 · 20 enrolled · United States
- Nov 30, 2016Phase 3 study in Macular EdemaNCT02980874 · 460 enrolled · United States, Australia, Austria and more
- Mar 27, 2017Phase 3 study in UveitisNCT03097315 · 38 enrolled · United States
- Apr 20, 2017Phase 2 study in Diabetes MellitusNCT03126786 · 71 enrolled · United States
- Jun 28, 2017Phase 3 study in Macular EdemaNCT03203447 · 325 enrolled · United States, Australia, Hungary and more
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 7 Clearside Biomedical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03203447Macular Edema · United States, Australia, Hungary and more | 3 | Terminated | Dec 18, 2018 | 325 |
| NCT03126786Diabetes Mellitus · United States | 2 | Completed | Apr 17, 2018 | 71 |
| NCT03097315Uveitis · United States | 3 | Completed | Jan 24, 2018 | 38 |
| NCT02980874Macular Edema · United States, Australia, Austria and more | 3 | Terminated | Dec 10, 2018 | 460 |
| NCT02949024Diabetes Mellitus · United States | 2 | Completed | Oct 17, 2017 | 20 |
| NCT02595398Uveitis · United States, India, Israel | 3 | Completed | Jan 18, 2018 | 160 |
| NCT01789320Uveitis · United States | 2 | Completed | Mar 2015 | 11 |
How it is read
Names in the registry
- “triamcinolone acetonide”, 4 entries
- “Triamcinolone Acetonide”, 2 entries
- “SC CLS-TA”, 2 entries
- “suprachoroidal CLS-TA”, 2 entries
- “Triamcinolone acetonide”, 2 entries
Conditions, from the studies’ own filings
- Macular Edema, 5 studies
- Uveitis, 3 studies
- Diabetes Mellitus, 2 studies
- Keloid, 2 studies
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.